Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $2.03, down -0.98% from its previous closing price of $2.05. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 2.8 million shares were traded.
Ratios:
To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.35 and its Current Ratio is at 9.35. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when MESSEMER DEBORAH M. sold 13,313 shares for $2.43 per share. The transaction valued at 32,351 led to the insider holds 144,316 shares of the business.
MESSEMER DEBORAH M. bought 13,313 shares of ALLO for $32,329 on Feb 18 ’25. On Feb 03 ’25, another insider, Douglas Earl Martin, who serves as the SVP, General Counsel of the company, sold 6,404 shares for $1.71 each. As a result, the insider received 10,951 and left with 587,848 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10640.75 while its Price-to-Book (P/B) ratio in mrq is 0.92.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $5.42, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is 3.67%, while the 200-Day Moving Average is calculated to be -15.64%.
Shares Statistics:
A total of 209.50M shares are outstanding, with a floating share count of 134.60M. Insiders hold about 35.80% of the company’s shares, while institutions hold 65.94% stake in the company.
Earnings Estimates
Investors are keenly observing as 9.0 analysts analyze and rate the current performance of Allogene Therapeutics Inc (ALLO) in the stock market.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.17 and -$1.42 for the fiscal current year, implying an average EPS of -$1.32. EPS for the following year is -$1.32, with 10.0 analysts recommending between -$1.02 and -$1.59.
